Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Eruptive Melanocytic Nevi: A Review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Fragrance contact allergy: a clinical review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. How does parental history of atopic disease predict the risk of atopic dermatitis in a child? A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

An advanced understanding of the pathogenesis of psoriasis has led to the development of multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor inhibitors, ustekinumab, interleukin-17 inhibitors, and guselkumab (an interleukin-23 inhibitor recently approved for psoriasis) are commercially available biologic agents for psoriasis. Evidence from clinical trials provides pertinent information regarding the safety and efficacy of biologic agents for psoriasis, which should be integrated into clinical decision making. However, disease presentations, disease severity, and comorbid conditions can complicate the choice of initial treatment, which underscores the importance of providing personalized therapy for patients with psoriasis. Furthermore, each biologic agent offers unique benefits and limitations for the treatment of patients with psoriasis. Here, evidence-based recommendations are presented and discussed regarding first-line biologic therapy options for patients with psoriasis and distinct comorbid conditions or patient-related factors. We discuss the comorbid conditions of psoriatic arthritis, multiple sclerosis, congestive heart failure, inflammatory bowel disease, hepatitis B, and latent tuberculosis. Moreover, we describe treatment recommendations for distinct patient populations with psoriasis, including pediatric patients with psoriasis and patients with psoriasis of childbearing potential and nursing.

Original languageEnglish
JournalAmerican Journal of Clinical Dermatology
Volume19
Issue number1
Pages (from-to)1-13
Number of pages13
ISSN1175-0561
DOIs
Publication statusPublished - Feb 2018

    Research areas

  • Biological Products/standards, Clinical Decision-Making/methods, Clinical Trials as Topic, Comorbidity, Evidence-Based Medicine/methods, Heart Failure/drug therapy, Hepatitis B/drug therapy, Humans, Inflammatory Bowel Diseases/drug therapy, Interleukin-17/antagonists & inhibitors, Interleukin-23/antagonists & inhibitors, Latent Tuberculosis/drug therapy, Multiple Sclerosis/drug therapy, Practice Guidelines as Topic, Psoriasis/drug therapy, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors

ID: 55202912